Temporal relationship between subclinical atrial fibrillation and embolic events

Circulation

Volumn 129, Issue 21, 2014, Pages 2094-2099

  Brambatti, Michela ^a,b   Connolly, Stuart J ^a   Gold, Michael R ^c   Morillo, Carlos A ^a   Capucci, Alessandro ^b   Muto, Carmine ^d   Lau, Chu P ^e   Van Gelder, Isabelle C ^f   Hohnloser, Stefan H ^g   Carlson, Mark ^h,i   Fain, Eric ⁱ   Nakamya, Juliet ^a   Mairesse, Georges H ^j   Halytska, Marta ^a   Deng, Wei Q ^a   Israel, Carsten W ^k   Healey, Jeff S ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d Cardiology Department   (Italy)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g GOETHE UNIVERSITY   (Germany)

^h ST JUDE MEDICAL   (United States)

ⁱ Clinique du Sud Luxembourg ^*

^j Cliniques du Sud Luxembourg   (Belgium)

^k EVANGELISCHES KRANKENHAUS   (Germany)

more..

Author keywords

Arrhythmia; Pacemaker; Stroke

Indexed keywords

ACETYLSALICYLIC ACID;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN ISCHEMIA; CARDIAC PATIENT; CEREBROVASCULAR ACCIDENT; DUAL CHAMBER PACEMAKER; ELECTROGRAPHY; EMBOLISM; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SYSTEMIC DISEASE;

ARRHYTHMIA; PACEMAKER; STROKE;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; EMBOLISM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PACEMAKER, ARTIFICIAL; PROSPECTIVE STUDIES; RISK FACTORS; STROKE; TIME FACTORS;

EID: 84901603173     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.007825     Document Type: Article

References (31)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke the Framingham Study. Stroke. 1991; 22 983-988.
2. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation population-based estimates. Am J Cardiol. 1998; 82 2N-9N.
3. Flaker GC, Belew K, Beckman K, Vidaillet H, Kron J, Safford R, Mickel M, Barrell P; AFFIRM Investigators. Asymptomatic atrial fibrillation demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005; 149 657-663.
4. Liao J, Khalid Z, Scallan C, Morillo C, O'Donnell M. Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke a systematic review. Stroke. 2007; 38 2935-2940.
5. Tayal AH, Tian M, Kelly KM, Jones SC, Wright DG, Singh D, Jarouse J, Brillman J, Murali S, Gupta R. Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. Neurology. 2008; 71 1696-1701.
6. Ziegler PD, Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Koehler JL, Hilker CE. Incidence of newly detected atrial arrhythmias via implantable devices in patients with a history of thromboembolic events. Stroke. 2010; 41 256-260.
7. Sinha AM, Diener HC, Morillo CA, Sanna T, Bernstein RA, Di Lazzaro V, Passman R, Beckers F, Brachmann J. Cryptogenic Stroke and Underlying Atrial Fibrillation (CRYSTAL AF) design and rationale. Am Heart J. 2010; 160 36-41. e1.
8. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012; 366 120-129.
9. Glotzer TV, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R, Cook J, Paraschos A, Love J, Radoslovich G, Lee KL, Lamas GA; MOST Investigators. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation. 2003; 107 1614-1619.
10. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C, Qi D, Ziegler PD. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk the TRENDS study. Circ Arrhythm Electrophysiol. 2009; 2 474-480.
11. Shively BK, Gelgand EA, Crawford MH. Regional left atrial stasis during atrial fibrillation and flutter determinants and relation to stroke. J Am Coll Cardiol. 1996; 27 1722-1729.
12. Freestone B, Lip GY. The endothelium and atrial fibrillation the prothrombotic state revisited. Hamostaseologie. 2008; 28 207-212.
13. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012; 60 2263-2270.
14. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation Virchow's triad revisited. Lancet. 2009; 373 155-166.
15. Inoue H, Nozawa T, Okumura K, Jong-Dae L, Shimizu A, Yano K. Prothrombotic activity is increased in patients with nonvalvular atrial fibrillation and risk factors for embolism. Chest. 2004; 126 687-692.
16. Black IW, Hopkins AP, Lee LC, Walsh WF. Left atrial spontaneous echo contrast a clinical and echocardiographic analysis. J Am Coll Cardiol. 1991; 18 398-404.
17. Daoud EG, Glotzer TV, Wyse DG, Ezekowitz MD, Hilker C, Koehler J, Ziegler PD; TRENDS Investigators. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data a subgroup analysis of TRENDS. Heart Rhythm. 2011; 8 1416-1423.
18. Hohnloser SH, Capucci A, Fain E, Gold MR, van Gelder IC, Healey J, Israel CW, Lau CP, Morillo C, Connolly SJ; ASSERT Investigators and Committees. Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT). Am Heart J. 2006; 152 442-447.
19. Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ; RE-LY Investigators. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score a subgroup analysis of the RE-LY trial. Ann Intern Med. 2011; 155 660-667.
20. Healey JS, Hart RG, Pogue J, Pfeffer MA, Hohnloser SH, De Caterina R, Flaker G, Yusuf S, Connolly SJ. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W). Stroke. 2008; 39 1482-1486.
21. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach the Euro heart survey on atrial fibrillation. Chest. 2010; 137 263-272.
22. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GY; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation antithrombotic therapy and prevention of thrombosis, 9th ed American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141(2 suppl) e531S-e575S.
23. Weigner MJ, Caulfield TA, Danias PG, Silverman DI, Manning WJ. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med. 1997; 126 615-620.
24. Israel CW, Grönefeld G, Ehrlich JR, Li YG, Hohnloser SH. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device implications for optimal patient care. J Am Coll Cardiol. 2004; 43 47-52.
25. Hindricks G, Pokushalov E, Urban L, Taborsky M, Kuck KH, Lebedev D, Rieger G, Pürerfellner H; XPECT Trial Investigators. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation results of the XPECT trial. Circ Arrhythm Electrophysiol. 2010; 3 141-147.
26. Khan IA. Transient atrial mechanical dysfunction (stunning) after cardioversion of atrial fibrillation and flutter. Am Heart J. 2002; 144 11-22.
27. Manning WJ, Silverman DI, Katz SE, Riley MF, Come PC, Doherty RM, Munson JT, Douglas PS. Impaired left atrial mechanical function after cardioversion relation to the duration of atrial fibrillation. J Am Coll Cardiol. 1994; 23 1535-1540.
28. Lamas G. How much atrial fibrillation is too much atrial fibrillation? N Engl J Med. 2012; 366 178-180.
29. Ip J, Waldo AL, Lip GY, Rothwell PM, Martin DT, Bersohn MM, Choucair WK, Akar JG, Wathen MS, Rohani P, Halperin JL. Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices rationale, design and clinical characteristics of the initially enrolled cohort of the IMPACT study. Am Heart J. 2009 364-270.
30. Healey JS, Martin JL, Duncan A, Connolly SJ, Ha AH, Morillo CA, Nair GM, Eikelboom J, Divakaramenon S, Dokainish H. Pacemaker-detected atrial fibrillation in patients with pacemakers prevalence, predictors, and current use of oral anticoagulation. Can J Cardiol. 2013; 29 224-228.
31. Anderson K, Benzauquen BS. Do patients with pacemaker-detected atrial fibrillation receive appropriate anticoagulation? Europace. 2011; 13 519.